Drug firm Bharat Parenterals on Saturday said it has received approval from the Drugs Controller General of India (DCGI) for favipiravir oral suspension, to be used for treatment of COVID-19 patients.
The company has received licence and authorisation from DCGI to manufacture and market favipiravir oral suspension l00mg/ml, Bharat Parenterals said in a regulatory filing.
Favipiravir, an antiviral drug, was approved in Japan in 2014 for the treatment of novel or re-emerging influenza virus infections.
Saina Nehwal & Parupalli Kashyap Divorce: Couple Decided To Part Ways After 7 Years Of Marraige & Two Decades Of Being Together
Wimbledon Prize Money: How Much Amount Did Winner Jannik Sinner & Runner Up Carlos Alcaraz Earn?
'600 Runs & He Is...': Ben Duckett Brutally Mocks Shubman Gill Before Indian Skipper's Dismissal On Day 4 Of IND vs ENG 3rd Test; Video
Wimbledon 2025 Final: Carlos Alcaraz Plays Insane Shot To Win 1st Set Against Jannik Sinner; Video
